Buformin hydrochloride

SKU: orb1306777

Description

Buformin hydrochloride

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1190-53-0
• MW: 193.68
• Purity: 97.83% (May vary between batches)
• Formula: C₆H₁₆ClN₅
• SMILES: Cl.CCCCNC(=N)NC(N)=N
• Target: AMPK
• Solubility: DMSO:60 mg/mL (309.79 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (10.33 mM)

Bioactivity

• In Vivo:
  Buformin hydrochloride (oral administation; 7.6 mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice.
• In Vitro:
  Buformin hydrochloride (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively. Buformin hydrochloride (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells. Buformin hydrochloride (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NSC528218, NSC-528218, NSC 528218, inhibit, Inhibitor, cervical cancer, breast cancer, 1-Butylbiguanide, AMP-activated protein kinase, agent, AMPK, antidiabetic, biguanide analog, BT474, Buformin, Buformin hydrochloride, Buformin Hydrochloride, SKBR3, Type II diabete

Compound Identifiers

PubChem CID

176516537